What Pyxis Oncology does

Pyxis Oncology is a Boston-based, NASDAQ-listed (PYXS) clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) and monoclonal antibody immunotherapies for difficult-to-treat cancers, with particular focus on recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Its lead asset, micvotabart pelidotin (MICVO, formerly PYX-201), is a first-in-class non-cellular targeting ADC directed at the extradomain-B splice variant of fibronectin (EDB+FN) in the tumor microenvironment, employing a three-pronged mechanism — direct tumor killing, bystander killing, and immunogenic cell death — via the Aur0101 auristatin payload. The company's technology stack is built on two platforms: the FACT (Flexible Antibody Conjugation Technology) ADC platform, originally developed by Pfizer and providing site-specific conjugation chemistry, linkers, and optimized payloads; and the APXiMAB antibody discovery platform, acquired via the 2024 Apexigen acquisition, which uses proprietary rabbit fusion cell lines and MLG humanization to generate high-affinity antibodies against difficult-to-drug targets. The broader pipeline includes Sotigalimab (a CD40 agonist acquired from Apexigen), PYX-106 (anti-Siglec-15), and PYX-102 (anti-KLRG1).

Pyxis Oncology has no commercial product and generates no product revenue. Its revenue model is currently limited to licensing and royalty streams — including an inherited royalty on a marketed product generated by the APXiMAB platform and a one-time $11M sale of royalty rights to a separate drug in December 2025. The company funds operations primarily through equity financing (a ~$50M post-IPO private placement closed February 2024) and is burning cash at an accelerating rate, with Q1 2026 R&D expenses of $20.0M and net loss of $23.3M versus $17.0M and $21.2M respectively in Q1 2025. With $42.5M in cash as of March 31, 2026, the stated runway extends only into Q4 2026, making capital availability the company's most acute near-term constraint. Customers are not yet end-patients or payers; investigational MICVO is accessed exclusively through clinical trial enrollment at U.S. sites, and the company's most commercially significant partner is Merck, supplying KEYTRUDA (pembrolizumab) for the MICVO combination trial.

Name

Pyxis Oncology

Legal name

Pyxis Oncology, Inc.

Website

https://pyxisoncology.com

Company type

Public

Founded year

2019

Operating status

Operating

Headcount range

51–100 employees

Short description

Pyxis Oncology is a Boston-based clinical-stage biopharmaceutical company developing antibody-drug conjugates and monoclonal antibody immunotherapies for difficult-to-treat cancers, with lead asset MICVO in Phase 1 development for recurrent/metastatic head and neck squamous cell carcinoma.

Ownership category

akta.pro rank

Product category

Cancer Therapeutics / Antibody-Drug Conjugates

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

Keywords

• Antibody-drug conjugates
• Immuno-oncology therapeutics
• Cancer antibody discovery
• Oncology clinical development
• Tumor microenvironment targeting

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Royalty Rights Sale: Sold royalty rights to a separate drug for $11 million in December 2025, extending cash runway through Q4 2026. Royalties from the APXiMAB platform's marketed product also represent an existing royalty stream inherited from Apexigen acquisition.
2. Investment / Equity Financing: Clinical-stage biotech with no product revenue. Generated quarterly revenue of $11.04 million (reported as a 'beat' in one period, though this likely reflects collaboration/royalty accounting). Primary funding source is private placement equity financing (e.g., $50M private placement closed February 2024 at $4.78/share).

Go-to-market motion3 records

Distribution channels1 record

Marketing channels6 records

Core offering

Pyxis Oncology is a clinical-stage biopharmaceutical company that develops investigational antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immuno-oncology therapeutics for difficult-to-treat cancers. Its lead asset, micvotabart pelidotin (MICVO, formerly PYX-201), is a first-in-class ADC targeting extradomain-B splice variant of fibronectin (EDB+FN) in the tumor microenvironment, currently in Phase 1/2 trials as monotherapy and in combination with Merck's KEYTRUDA for recurrent/metastatic head and neck squamous cell carcinoma. The company leverages two proprietary platforms — the FACT ADC platform (originating from Pfizer) and the APXiMAB antibody discovery platform (acquired via Apexigen) — to support next-generation ADC and immuno-oncology candidates including PYX-106 (anti-Siglec-15) and Sotigalimab (CD40 agonist).

Product overview

Pyxis Oncology is a clinical-stage biopharmaceutical company offering a platform-plus-modules architecture centered on a differentiated portfolio of antibody-drug conjugate (ADC) and monoclonal antibody (mAb) immuno-oncology assets. The FACT Platform (Flexible Antibody Conjugation Technology, originated by Pfizer) provides site-specific conjugation chemistry, linkers, and payloads for next-generation ADCs, while the APXiMAB Platform provides antibody discovery via proprietary rabbit fusion cell lines and MLG humanization. Built on these platforms, the lead clinical asset is the ADC micvotabart pelidotin (MICVO, formerly PYX-201) targeting extradomain-B fibronectin in solid tumors, supplemented by the immuno-oncology candidates PYX-106 (anti-Siglec-15 mAb), PYX-102 (anti-KLRG1 mAb), and the CD40 agonist Sotigalimab (formerly APX005M) acquired through the Apexigen acquisition. Together, these products enable Pyxis Oncology to develop both monotherapies and combination regimens (e.g., MICVO + KEYTRUDA/pembrolizumab) targeting difficult-to-treat cancers.

Differentiator

Problem solved

Functional benefit

Brands

• MICVO (micvotabart pelidotin): Lead investigational antibody-drug conjugate (ADC) targeting extradomain-B splice variant of fibronectin (EDB+FN), formerly known as PYX-201.
• FACT (Flexible Antibody Conjugation Technology)
• APXiMAB

Products and services

• Micvotabart Pelidotin (MICVO, formerly PYX-201) First-in-class investigational antibody-drug conjugate (ADC) targeting extradomain-B splice variant of fibronectin (EDB+FN), an extracellular matrix protein selectively overexpressed in tumor microenvironment. In Phase 1 trials as monotherapy and in combination with KEYTRUDA (pembrolizumab) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) and other solid tumors. U.S. FDA granted Fast Track Designation for R/M HNSCC.
• PYX-106 Highly differentiated anti-Siglec-15 monoclonal antibody designed to reverse Siglec-15 mediated immune suppression and enhance cytotoxic activity in human lymphocytes; was in Phase 1 development for advanced solid tumors with data anticipated by year-end.
• Sotigalimab (formerly APX005M / PYX-107) CD40 agonistic monoclonal antibody acquired via the Apexigen acquisition, described as a potential best-in-class CD40 agonist. Investigated across multiple oncology indications including metastatic melanoma, pancreatic adenocarcinoma, esophageal/GEJ cancers, and sarcoma, both as monotherapy and in combination with chemotherapy, radiotherapy, and checkpoint inhibitors.
• PYX-102 Anti-KLRG1 antibody that enhances cytotoxic activity of CD8 T cells from PBMC and human tumor samples by blocking the interaction between KLRG1 and cadherins.

Quantifiable outcome

• 46% confirmed objective response rate as monotherapy and 71% in combination with pembrolizumab in R/M HNSCC Phase 1 trial
• +3 more outcomes

Named customers1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Nine partnerships are on record, tiered major m&a — platform transforming, flagship clinical combination partner, core technology platform originator and advisory relationship.

• Apexigenmajor m&a — platform transformingStrategic or Co-development Partner · 1 May 2023Pyxis Oncology completed acquisition of Apexigen in an all-stock deal valued at approximately $10.7 million (with prior announcement value of ~$16 million). Acquisition expanded Pyxis Oncology's antibody and ADC platform, added a Phase 2 candidate and royalty stream, and brought in the APXiMAB antibody discovery platform and Sotigalimab (CD40 agonist).
• Merck (KEYTRUDA / pembrolizumab)flagship clinical combination partnerStrategic or Co-development PartnerClinical combination partnership evaluating MICVO with Merck's KEYTRUDA (pembrolizumab) in Phase 1/2 study (NCT06795412) for recurrent/metastatic head and neck squamous cell carcinoma. KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Updated combination data expected in 2H 2026.
• Pfizercore technology platform originatorStrategic or Co-development PartnerFACT (Flexible Antibody Conjugation Technology) ADC platform was developed by Pfizer and provides Pyxis Oncology with site-specific conjugation chemistries, improved linker technology, and optimized payloads for next-generation ADC development. Pfizer is also listed as a financial investor on the company website.
• University of Colorado Cancer Centeradvisory relationshipOthersPaul A. Bunn, Jr, M.D., FASCO, FACP, FAAAS from University of Colorado Cancer Center serves on Pyxis Oncology's Clinical and Translational Medicine Advisory Board.
• UT MD Anderson Cancer Centeradvisory relationshipOthersGiulio Draetta, M.D., Ph.D. from UT MD Anderson Cancer Center serves on Pyxis Oncology's Clinical and Translational Medicine Advisory Board.
• Yale University, Yale Cancer Centeradvisory relationshipOthersPatricia LoRusso, D.O., Ph.D. (hc) from Yale University, Yale Cancer Center serves on Pyxis Oncology's Clinical and Translational Medicine Advisory Board.
• UPMC Hillman Cancer Center, University of Pittsburghadvisory relationshipOthersJason J. Luke, M.D., FACP from UPMC Hillman Cancer Center, University of Pittsburgh serves on Pyxis Oncology's Clinical and Translational Medicine Advisory Board.
• NEXT Oncologyadvisory relationshipOthersAnthony W. Tolcher, M.D., FRCPC, FACP from NEXT Oncology serves on Pyxis Oncology's Clinical and Translational Medicine Advisory Board.
• BioMarin Pharmaceuticaladvisory relationshipOthersRobert Baffi, Ph.D., MBA, President of Global Manufacturing & Technical Operations at BioMarin, serves on Pyxis Oncology's Technical Advisory Board.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Mersana Therapeutics: Mersana Therapeutics is a clinical-stage ADC developer with proprietary platforms (Dolasynthen, Immunosynthen) advancing first-in-class and best-in-class ADCs in oncology, comparable to Pyxis Oncology in stage, business model, and ADC-centric clinical focus.
• ADC Therapeutics: ADC Therapeutics is a commercial-stage ADC company developing pyrrolobenzodiazepine-based ADCs (Zynlonta) for hematologic and solid tumors, comparable to Pyxis Oncology as a fellow ADC-focused oncology developer with platform-based pipeline strategy.
• ImmunoGen (AbbVie): ImmunoGen developed the ADC platform behind Elahere (mirvetuximab) and was acquired by AbbVie in 2024, making it a direct precedent for ADC-platform M&A and a comparable ADC developer in ovarian and other solid tumors.

Emerging players

• ProfoundBio: ProfoundBio is a clinical-stage ADC developer with multiple candidates in oncology including FRα and CDH17-targeted ADCs, comparable to Pyxis Oncology in clinical stage, ADC focus, and targeted-oncology development approach.
• Bolt Biotherapeutics: Bolt Biotherapeutics is a clinical-stage immuno-oncology company developing immune-stimulating antibody conjugates (ISACs) that combine ADC-like targeting with innate immune activation, comparable to Pyxis in stage, oncology focus, and antibody-conjugate therapeutic modality.
• Tubulis: Tubulis is a clinical-stage ADC developer focused on next-generation linkers, payloads, and conjugation chemistries to improve therapeutic index, directly comparable to Pyxis's FACT platform focus on linker and conjugation technology advancement.
• Mythic Therapeutics: Mythic Therapeutics is a clinical-stage ADC developer focused on solid tumors, comparable to Pyxis Oncology as a fellow emerging ADC biotech targeting oncology indications with antibody-conjugate technology.

Broad incumbents

• Daiichi Sankyo: Daiichi Sankyo co-developed Enhertu and Datroway with AstraZeneca, making it the leading commercial ADC player and a broad incumbent whose pipeline defines the competitive benchmark for clinical-stage ADC developers like Pyxis Oncology.
• AstraZeneca: AstraZeneca is a global oncology leader with the Enhertu/Datroway ADC franchise and broad immuno-oncology portfolio, serving as a broad incumbent competitor whose checkpoint-inhibitor combination strategy parallels Pyxis Oncology's MICVO + KEYTRUDA development path.
• Pfizer: Pfizer originated the FACT ADC platform licensed to Pyxis Oncology and maintains a broad oncology and ADC pipeline (including Padcev via Seagen acquisition), making it both a technology licensor and broad incumbent competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/pyxisoncology
• LinkedInlinkedin.com/company/pyxis-oncology

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Subsidiaries1 record

Funding overview

Funding rounds4 records

Investors26 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pyxis Oncology